BRAF and melanoma: Furthermore, in patients with advanced unresectable melanoma who had either progressed on ipilimumab or a BRAF or MEK inhibitor (if BRAFV600E/K mutant), pembrolizumab reduced the risk of disease progression as compared with the standard‐of‐care chemotherapy [97].